Whanin Pharm (016580) - Net Assets

Latest as of December 2025: ₩421.01 Billion KRW ≈ $285.31 Million USD

Based on the latest financial reports, Whanin Pharm (016580) has net assets worth ₩421.01 Billion KRW (≈ $285.31 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩478.89 Billion ≈ $324.54 Million USD) and total liabilities (₩57.88 Billion ≈ $39.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 016580 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩421.01 Billion
% of Total Assets	87.91%
Annual Growth Rate	8.85%
5-Year Change	32.72%
10-Year Change	91.25%
Growth Volatility	11.08

Whanin Pharm - Net Assets Trend (2009–2025)

This chart illustrates how Whanin Pharm's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Whanin Pharm to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Whanin Pharm (2009–2025)

The table below shows the annual net assets of Whanin Pharm from 2009 to 2025. For live valuation and market cap data, see how much is Whanin Pharm worth.

Year	Net Assets	Change
2025-12-31	₩421.01 Billion ≈ $285.31 Million	+11.97%
2024-12-31	₩376.00 Billion ≈ $254.81 Million	+4.97%
2023-12-31	₩358.21 Billion ≈ $242.75 Million	+7.27%
2022-12-31	₩333.93 Billion ≈ $226.30 Million	+5.27%
2021-12-31	₩317.23 Billion ≈ $214.98 Million	+6.95%
2020-12-31	₩296.60 Billion ≈ $201.00 Million	+8.07%
2019-12-31	₩274.46 Billion ≈ $186.00 Million	+5.73%
2018-12-31	₩259.58 Billion ≈ $175.92 Million	+6.79%
2017-12-31	₩243.08 Billion ≈ $164.73 Million	+10.43%
2016-12-31	₩220.13 Billion ≈ $149.18 Million	+35.44%
2012-12-31	₩162.53 Billion ≈ $110.14 Million	+8.46%
2011-12-31	₩149.85 Billion ≈ $101.55 Million	+38.20%
2009-12-31	₩108.44 Billion ≈ $73.49 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Whanin Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 319.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩368.15 Billion	87.44%
Other Components	₩52.86 Billion	12.56%
Total Equity	₩421.01 Billion	100.00%

Whanin Pharm Competitors by Market Cap

The table below lists competitors of Whanin Pharm ranked by their market capitalization.

Company	Market Cap
Bogota Financial Corp NASDAQ:BSBK	$106.38 Million
Daihan Pharmaceutical Co.Ltd KQ:023910	$106.39 Million
Tillys Inc NYSE:TLYS	$106.41 Million
Spyrosoft Spólka Akcyjna F:2NP	$106.43 Million
Severn Trent PLC LSE:SVT	$106.32 Million
icad inc NASDAQ:ICAD	$106.31 Million
Yi Jinn Industrial Co Ltd TW:1457	$106.31 Million
Chung Lien Transportation Co Ltd TWO:5604	$106.25 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Whanin Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 376,001,534,030 to 421,006,997,990, a change of 45,005,463,960 (12.0%).
Net income of 13,595,213,600 contributed positively to equity growth.
Dividend payments of 4,580,121,000 reduced retained earnings.
New share issuances of 11,395,923,000 increased equity.
Other factors increased equity by 24,594,448,360.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩13.60 Billion	+3.23%
Dividends Paid	₩4.58 Billion	-1.09%
Share Issuances	₩11.40 Billion	+2.71%
Other Changes	₩24.59 Billion	+5.84%
Total Change	₩-	11.97%

Book Value vs Market Value Analysis

This analysis compares Whanin Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.40x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 0.65x to 0.40x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩15922.08	₩10280.00	x
2018-12-31	₩17002.90	₩10280.00	x
2019-12-31	₩17932.54	₩10280.00	x
2020-12-31	₩19395.66	₩10280.00	x
2021-12-31	₩20759.68	₩10280.00	x
2022-12-31	₩21845.15	₩10280.00	x
2023-12-31	₩23462.75	₩10280.00	x
2024-12-31	₩24628.27	₩10280.00	x
2025-12-31	₩25880.94	₩10280.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Whanin Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.23%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 5.33%
• Asset Turnover: 0.53x
• Equity Multiplier: 1.14x
Recent ROE (3.23%) is below the historical average (8.72%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2009	13.31%	14.52%	0.84x	1.10x	₩3.59 Billion
2010	14.36%	16.31%	0.00x	0.00x	₩5.23 Billion
2011	9.75%	13.28%	0.66x	1.11x	₩-373.40 Million
2012	9.72%	14.73%	0.59x	1.12x	₩-456.41 Million
2016	7.45%	11.60%	0.58x	1.11x	₩-5.62 Billion
2017	11.18%	18.37%	0.54x	1.13x	₩2.86 Billion
2018	8.29%	13.91%	0.54x	1.11x	₩-4.44 Billion
2019	6.83%	11.75%	0.52x	1.11x	₩-8.68 Billion
2020	7.90%	13.62%	0.52x	1.11x	₩-6.22 Billion
2021	8.41%	15.00%	0.50x	1.11x	₩-5.03 Billion
2022	7.17%	12.02%	0.54x	1.11x	₩-9.43 Billion
2023	8.31%	12.92%	0.57x	1.12x	₩-6.05 Billion
2024	6.22%	9.01%	0.61x	1.13x	₩-14.22 Billion
2025	3.23%	5.33%	0.53x	1.14x	₩-28.51 Billion

Industry Comparison

This section compares Whanin Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $623,217,776,252
Average return on equity (ROE) among peers: 2.44%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Whanin Pharm (016580)	₩421.01 Billion	13.31%	0.14x	$106.36 Million
Dongwha Pharm.Co.Ltd (000020)	$401.44 Billion	2.16%	0.60x	$100.87 Million
Yuhan Corp. (000100)	$2.01 Trillion	4.74%	0.23x	$3.91 Billion
Yuhan Corp Preferred (000105)	$2.15 Trillion	3.29%	0.37x	$52.61 Million
Yuyu Pharma (000220)	$123.37 Billion	-4.85%	0.58x	$42.66 Million
Yuyu Pharma Inc (000225)	$128.69 Billion	-1.72%	0.50x	$15.37 Million
Yuyu Pharma Inc (000227)	$123.37 Billion	-4.85%	0.58x	$42.45 Million
Ildong Holdings Co Ltd (000230)	$349.98 Billion	5.99%	1.02x	$56.55 Million
Samil Pharm (000520)	$62.87 Billion	0.00%	0.77x	$104.16 Million
Donga Socio Holdings (000640)	$514.60 Billion	3.03%	0.92x	$374.79 Million
Jw Pharmac (001060)	$369.37 Billion	16.65%	0.64x	$416.42 Million

About Whanin Pharm

KO:016580 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$106.36 Million

₩156.95 Billion KRW

Market Cap Rank

#19054 Global

#931 in Korea

Share Price

₩10280.00

Change (1 day)

+0.39%

52-Week Range

₩10020.00 - ₩13130.00

All Time High

₩24391.10